Amnestix Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $6.3M

Amnestix General Information

Description

Operator of a biopharmaceutical company intended to develop drugs for memory-related disorders. The company focuses on developing small-molecule compounds that could be used in the treatment of Alzheimer's disease, dementia, and similar neurological conditions.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 800 Airport Road
  • Suite 508
  • Burlingame, CA 94010
  • United States
+1 (650)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Other Healthcare
Acquirer
Vertical(s)
Corporate Office
  • 800 Airport Road
  • Suite 508
  • Burlingame, CA 94010
  • United States
+1 (650)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Amnestix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 08-Jun-2008 $6.3M Completed Generating Revenue
2. Early Stage VC (Series A) 09-Mar-2007 Completed Startup
1. University Spin-Out 01-Jan-2006 Completed Startup
To view Amnestix’s complete valuation and funding history, request access »

Amnestix Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view Amnestix’s complete cap table history, request access »

Amnestix Patents

Amnestix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20100160297-A1 Compounds for pim kinase inhibition and for treating malignancy Inactive 12-May-2008
EP-2296472-A1 Compounds for rho kinase inhibition and for improving learning and memory Inactive 12-May-2008
US-20110237600-A1 Compounds for improving learning and memory Inactive 12-May-2008
CA-2723472-A1 Compounds for rho kinase inhibition and for improving learning and memory Inactive 12-May-2008
AU-2009257926-A1 Compounds for rho kinase inhibition and for improving learning and memory Inactive 12-May-2008 A61K31/47
To view Amnestix’s complete patent history, request access »

Amnestix Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Brain Trust Accelerator Fund Venture Capital Minority
To view Amnestix’s complete investors history, request access »

Amnestix FAQs

  • When was Amnestix founded?

    Amnestix was founded in 2006.

  • Where is Amnestix headquartered?

    Amnestix is headquartered in Burlingame, CA.

  • What industry is Amnestix in?

    Amnestix’s primary industry is Biotechnology.

  • Is Amnestix a private or public company?

    Amnestix is a Private company.

  • What is the current valuation of Amnestix?

    The current valuation of Amnestix is .

  • What is Amnestix’s current revenue?

    The current revenue for Amnestix is .

  • How much funding has Amnestix raised over time?

    Amnestix has raised $520K.

  • Who are Amnestix’s investors?

    Brain Trust Accelerator Fund has invested in Amnestix.

  • When was Amnestix acquired?

    Amnestix was acquired on 08-Jun-2008.

  • Who acquired Amnestix?

    Amnestix was acquired by X-Pol Biotech.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »